Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Resnick

Neurology Bay Harbor Islands, FL Doctor of Osteopathy

NPI 1972553816 CMS profile 89696

1111 Kane Concourse, Suite 504, Bay Harbor Islands, FL 33154

Open in the dashboard

General payments

$9,024

490 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Resnick of Bay Harbor Islands, FL is reported in the CMS Open Payments database as having received $9,024 across 490 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,054 104
2024 General $1,385 78
2023 General $1,630 83
2022 General $1,693 96
2021 General $1,276 78
2020 General $380 23
2019 General $605 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Resnick
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Steven Resnick were reported at $2,054. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Steven Resnick Neurology median Middle half National median
2019 $605 $474 $118–$2,177 $163
2020 $380 $367 $82–$2,309 $114
2021 $1,276 $438 $104–$2,547 $132
2022 $1,693 $442 $103–$2,388 $149
2023 $1,630 $464 $119–$2,312 $160
2024 $1,385 $468 $119–$2,323 $164
2025 $2,054 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,359 143 payments
  2. Pfizer Inc. $700 41 payments
  3. Ge Healthcare $478 22 payments
  4. Biohaven Pharmaceutical Holding Company Ltd. $463 31 payments
  5. Teva Pharmaceuticals USA, Inc. $442 20 payments
  6. Allergan Inc. $346 32 payments
  7. Alexion Pharmaceuticals, Inc. $327 15 payments
  8. Biohaven Pharmaceuticals, Inc. $308 26 payments
  9. UCB, Inc. $250 13 payments
  10. Argenx US, Inc. $231 8 payments
  11. Other $3,119 139 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,851 487 payments
  2. Education $173 3 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,201 72 payments
  2. QULIPTA $804 58 payments
  3. NURTEC ODT Primary Care $771 57 payments
  4. NURTEC ODT Pain $600 33 payments
  5. ZAVZPRET $554 30 payments
  6. BOTOX Botox Therapeutic $526 27 payments
  7. BOTOX Neuroscience $279 15 payments
  8. BOTOX Hyperhydrosis $268 22 payments
  9. AIMOVIG $240 11 payments
  10. ULTOMIRIS $226 11 payments
  11. Other $4,253 212 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 63 drugs

Part D claims

2,755

Median for Neurology: 833

Drug cost

$791,270

Median for Neurology: $202,670

Branded share of claims

34.3%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Kesimpta Pen Ofatumumab Brand 18 $168,872
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 26 $124,294
Avonex (4 Pack) Interferon Beta-1a Brand 12 $99,098
Austedo Deutetrabenazine Brand 12 $89,722
Nurtec Odt Rimegepant Sulfate Brand 53 $74,918
Emgality Pen Galcanezumab-Gnlm Brand 69 $56,769
Aimovig Autoinjector Erenumab-Aooe Brand 25 $34,568
Qulipta Atogepant Brand 21 $23,165
Vimpat Lacosamide Brand 17 $21,561
Lamictal Lamotrigine Brand 13 $16,973

The 10 drugs with the highest cost, of 63 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$363,983

Of which drugs: $127,057

Medicare patients

584

Average age 77

Services billed

27,354

311 women, 273 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 42%
Diabetes 34%
Depression 34%
Chronic kidney disease 26%
Osteoporosis 25%
Atrial fibrillation 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 43 25,500 $127,056

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
$180 21 —
BOTOX
$175 — 25,500
UBRELVY
$101 — —
OFEV
$84 — —
VYEPTI
$79 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

490 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record